The U.S. Supreme Court affirmed the constitutionality of the Affordable Care Act provision requiring insurance coverage of specified preventive healthcare services without patient cost sharing. This ruling ensures continued coverage of services including BRCA testing and colorectal cancer screening. The decision impacts diagnostics companies and pharmaceutical firms providing preventive medications, sustaining existing patient access rights.